Literature DB >> 18091404

A novel pathway for the management of hypertension for hospitalized patients.

Eyal Herzog1, Olivier Frankenberger, Emad Aziz, Sripal Bangalore, Sandhya Balaram, E John Nasrallah, Stanley Cortell, Franz H Messerli.   

Abstract

About 65 million Americans, one fourth of the adult population in the United States, and over 1 billion people worldwide have hypertension (HTN). HTN therefore is present in 1 of every 4 patients admitted to any US hospital. Surprisingly, no guidelines are available for the management of inpatient HTN. Based on a comprehensive search of the literature we are proposing a pathway for the management of HTN in nonpregnant hospitalized patients. The pathway provides a definition and clinical assessment of HTN for patients admitted to the hospital. The assessment is followed by an organ/system based therapeutic approach specifying timing, blood pressure goals, recommended antihypertensive drug therapy and the sequence of add-on drugs. The pathway specifically discusses assessment and management of HTN in patients with (1) acute aortic syndrome, (2) acute neurologic syndrome, (3) acute coronary syndrome, (4) congestive heart failure, (5) renal failure, and (6) secondary forms. Finally, the pathway provides a step by step recommendation for the management of in hospital HTN and of hypertensive emergencies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18091404     DOI: 10.1097/HPC.0b013e318160c3a7

Source DB:  PubMed          Journal:  Crit Pathw Cardiol        ISSN: 1535-2811


  2 in total

1.  Treatment of hypertension in the inpatient setting: use of intravenous labetalol and hydralazine.

Authors:  Alan B Weder; Steven Erickson
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-01       Impact factor: 3.738

2.  Clevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysis.

Authors:  W Frank Peacock; Joseph Varon; Ramin Ebrahimi; Lala Dunbar; Charles V Pollack
Journal:  Blood Press Suppl       Date:  2010-11-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.